DrugCite
Search

OFLOCET

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Oflocet Adverse Events Reported to the FDA Over Time

How are Oflocet adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Oflocet, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Oflocet is flagged as the suspect drug causing the adverse event.

Most Common Oflocet Adverse Events Reported to the FDA

What are the most common Oflocet adverse events reported to the FDA?

Pyrexia
69 (2.01%)
Thrombocytopenia
69 (2.01%)
Renal Failure Acute
60 (1.75%)
Drug Interaction
51 (1.48%)
Agranulocytosis
43 (1.25%)
Confusional State
43 (1.25%)
International Normalised Ratio Incr...
43 (1.25%)
Renal Failure
43 (1.25%)
Neutropenia
41 (1.19%)
Alanine Aminotransferase Increased
38 (1.11%)
Anaemia
36 (1.05%)
Show More Show More
Arthralgia
34 (.99%)
Toxic Skin Eruption
33 (.96%)
Diarrhoea
31 (.9%)
Gamma-glutamyltransferase Increased
31 (.9%)
Tendonitis
30 (.87%)
Vascular Purpura
30 (.87%)
Cytolytic Hepatitis
29 (.84%)
Rash Maculo-papular
28 (.81%)
Cholestasis
27 (.79%)
Eosinophilia
27 (.79%)
Convulsion
26 (.76%)
Acute Generalised Exanthematous Pus...
24 (.7%)
Blood Creatinine Increased
24 (.7%)
Rhabdomyolysis
24 (.7%)
Hypotension
23 (.67%)
Leukopenia
23 (.67%)
Pancytopenia
23 (.67%)
Drug Rash With Eosinophilia And Sys...
22 (.64%)
Aspartate Aminotransferase Increase...
21 (.61%)
Blood Alkaline Phosphatase Increase...
21 (.61%)
Dehydration
21 (.61%)
Encephalopathy
21 (.61%)
Purpura
21 (.61%)
Hyperthermia
20 (.58%)
Sepsis
20 (.58%)
Septic Shock
20 (.58%)
Toxic Epidermal Necrolysis
20 (.58%)
General Physical Health Deteriorati...
19 (.55%)
Inflammation
19 (.55%)
Myoclonus
19 (.55%)
Pruritus
19 (.55%)
Somnolence
19 (.55%)
Asthenia
18 (.52%)
Muscular Weakness
17 (.49%)
Myalgia
17 (.49%)
Rash
17 (.49%)
Cardiac Failure
16 (.47%)
Stevens-johnson Syndrome
16 (.47%)
Abdominal Pain
15 (.44%)
Blood Creatine Phosphokinase Increa...
14 (.41%)
Cardiac Arrest
14 (.41%)
Haematoma
14 (.41%)
Haematuria
14 (.41%)
Hepatitis Cholestatic
14 (.41%)
Rash Erythematous
14 (.41%)
Vertigo
14 (.41%)
Vomiting
14 (.41%)
Aplastic Anaemia
13 (.38%)
Death
13 (.38%)
Erythema
13 (.38%)
Hepatitis
13 (.38%)
Tumour Lysis Syndrome
13 (.38%)
Agitation
12 (.35%)
Dermatitis Bullous
12 (.35%)
Infection
12 (.35%)
Atrial Fibrillation
11 (.32%)
Coma
11 (.32%)
Staphylococcal Infection
11 (.32%)
Alopecia
10 (.29%)
Balanitis Candida
10 (.29%)
Dysgeusia
10 (.29%)
Epilepsy
10 (.29%)
Hyperkalaemia
10 (.29%)
Hypertension
10 (.29%)
Leukocytoclastic Vasculitis
10 (.29%)
Lung Disorder
10 (.29%)
Memory Impairment
10 (.29%)
Renal Pain
10 (.29%)
Tachycardia
10 (.29%)
Tendon Disorder
10 (.29%)
Urticaria
10 (.29%)
Vision Blurred
10 (.29%)
Condition Aggravated
9 (.26%)
Disorientation
9 (.26%)
Haemoglobin Decreased
9 (.26%)
Hepatic Enzyme Increased
9 (.26%)
Lipase Increased
9 (.26%)
Loss Of Consciousness
9 (.26%)
Overdose
9 (.26%)
Platelet Count Decreased
9 (.26%)
Transaminases Increased
9 (.26%)
Urinary Tract Infection
9 (.26%)
Cerebellar Syndrome
8 (.23%)
Dermatitis Exfoliative
8 (.23%)
Diplopia
8 (.23%)
Dyspnoea
8 (.23%)
Gait Disturbance
8 (.23%)
Haptoglobin Decreased
8 (.23%)
Hyperbilirubinaemia
8 (.23%)
Jaundice
8 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Oflocet, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oflocet is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Oflocet

What are the most common Oflocet adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Oflocet, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oflocet is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Oflocet According to Those Reporting Adverse Events

Why are people taking Oflocet, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
124
Urinary Tract Infection
79
Prostatitis
31
Pyelonephritis
31
Lung Disorder
28
Infection
28
Show More Show More
Pneumonia
20
Bronchitis
18
Sepsis
18
Staphylococcal Infection
16
Product Used For Unknown Indication
15
Lung Infection
13
Bronchopneumopathy
11
Osteitis
10
Diarrhoea
9
Prophylaxis
8
Intervertebral Discitis
8
Sinusitis
8
Endocarditis
8
Pyrexia
7
Ear Infection
7
Infection Prophylaxis
7
Diabetic Foot
7
Bacteraemia
7
Erysipelas
6
Superinfection
6
Antibiotic Therapy
6
Pyelonephritis Acute
5
Bacterial Infection
5
Drug Exposure During Pregnancy
5
Meningitis
5
Antibiotic Prophylaxis
5
Device Related Infection
4
Localised Infection
4
Diverticulum
4
Inflammation
4
Unevaluable Event
4
Arthritis Bacterial
4
Renal Abscess
4
Sigmoiditis
4
Escherichia Sepsis
4
Skin Lesion
3
Urosepsis
3
Fasciitis
3
Staphylococcal Bacteraemia
3
Arterial Injury
3
Arthritis
3
Sinobronchitis
3
Anal Abscess
3
Escherichia Infection
3
Liver Abscess
3

Oflocet Case Reports

What Oflocet safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Oflocet. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Oflocet.